ReviewJournal of physiology and biochemistry2026
The impact of bariatric and metabolic surgery on the levels of circulating growth differentiation factor 15 in humans.
Review in Journal of physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a known risk factor cardiovascular disease, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH), characterized by a state of chronic inflammation. In this stress context, many hepatokines and adipokines may be released, including Growth Differentiation Factor 15 (GDF15). GDF15 is involved in the regulation of appetite and metabolism, showing potential for the treatment of obesity and related comorbidities. This review aimed to evaluate the impact of bariatric and metabolic surgery (BMS) in the levels of circulating GDF15 in individuals with obesity. Considering the studies available, reporting GDF15 levels before and 12 months after BMS, the profile of GDF15 changes was not a consensus, and was not fully explained by differences in the characterization of the population in each study. This review also discusses the multiple sources of GDF15 in obesity and in response to its surgical treatment, where pathological, pharmacological, and behavioral factors may all be important contributors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.